ECSP10010471A - Agonistas nicotínicos alfa 7 y antipsicóticos - Google Patents

Agonistas nicotínicos alfa 7 y antipsicóticos

Info

Publication number
ECSP10010471A
ECSP10010471A EC2010010471A ECSP10010471A ECSP10010471A EC SP10010471 A ECSP10010471 A EC SP10010471A EC 2010010471 A EC2010010471 A EC 2010010471A EC SP10010471 A ECSP10010471 A EC SP10010471A EC SP10010471 A ECSP10010471 A EC SP10010471A
Authority
EC
Ecuador
Prior art keywords
antipsychotic
alfa
nicotine agonists
nicotine
agonists
Prior art date
Application number
EC2010010471A
Other languages
English (en)
Inventor
Merouane Bencherif
Gregory J Gatto
Kristen G Jordan
Sharon R Letchworth
Terry Hauser
Original Assignee
Targacept Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targacept Inc filed Critical Targacept Inc
Publication of ECSP10010471A publication Critical patent/ECSP10010471A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La presente Invención se relaciona con una combinación sinérgica de un agonista nicotínico alfa 7 (?7) y un agente antipsicótico.
EC2010010471A 2008-02-13 2010-09-09 Agonistas nicotínicos alfa 7 y antipsicóticos ECSP10010471A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2828208P 2008-02-13 2008-02-13

Publications (1)

Publication Number Publication Date
ECSP10010471A true ECSP10010471A (es) 2010-10-30

Family

ID=40902222

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010471A ECSP10010471A (es) 2008-02-13 2010-09-09 Agonistas nicotínicos alfa 7 y antipsicóticos

Country Status (25)

Country Link
US (1) US20110059947A1 (es)
EP (2) EP2254598B1 (es)
JP (1) JP2011511845A (es)
KR (1) KR20100113163A (es)
CN (2) CN101977628A (es)
AU (1) AU2009214625A1 (es)
BR (1) BRPI0907570A2 (es)
CA (1) CA2715268A1 (es)
CO (1) CO6290706A2 (es)
CY (1) CY1114492T1 (es)
DK (1) DK2254598T3 (es)
EC (1) ECSP10010471A (es)
ES (1) ES2430622T3 (es)
HR (1) HRP20130749T1 (es)
IL (1) IL207389A0 (es)
MX (1) MX2010008875A (es)
NZ (1) NZ587312A (es)
PL (1) PL2254598T3 (es)
PT (1) PT2254598E (es)
RS (1) RS52941B (es)
RU (1) RU2481123C2 (es)
SG (1) SG188144A1 (es)
SI (1) SI2254598T1 (es)
WO (1) WO2009102962A2 (es)
ZA (1) ZA201005999B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8314119B2 (en) * 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
SA08290475B1 (ar) * 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
US9464078B2 (en) 2010-09-23 2016-10-11 Abbvie Inc. Monohydrate of azaadamantane derivatives
PH12013501509A1 (en) * 2011-01-18 2019-08-07 Targacept Inc Treatment of cognitive dysfunction in schizophrenia
EP2704573A4 (en) 2011-05-03 2014-10-15 Merck Sharp & Dohme AMINOMETHYL biaryl BENZOTRIAZOL DERIVATIVES
JPWO2014054635A1 (ja) * 2012-10-02 2016-08-25 大日本住友製薬株式会社 イミダゾール誘導体
JP6807094B2 (ja) * 2016-04-29 2021-01-06 国立大学法人秋田大学 クロザピン又はその誘導体の血中薬剤濃度上昇リスク判定方法及び薬剤投与量判定方法
ES3001152T3 (es) 2016-12-20 2025-03-04 Lts Lohmann Therapie Systeme Ag Sistema terapéutico transdérmico que contiene asenapina y polisiloxano o poliisobutileno
PL3338768T3 (pl) 2016-12-20 2020-05-18 Lts Lohmann Therapie-Systeme Ag Transdermalny system terapeutyczny zawierający asenapinę
CN108727416B (zh) * 2017-04-20 2021-03-09 北京大学 三环杂芳香体系酰胺衍生物及其制备和用途
WO2019002204A1 (en) 2017-06-26 2019-01-03 Lts Lohmann Therapie-Systeme Ag TRANSDERMAL THERAPEUTIC SYSTEM CONTAINING ASENAPINE AND SILICONE-TYPE ACRYLIC HYBRID POLYMER
CN107469087A (zh) * 2017-09-10 2017-12-15 孙永丽 用于治疗精神病的制剂
EP3810099A1 (en) 2018-06-20 2021-04-28 LTS Lohmann Therapie-Systeme AG Transdermal therapeutic system containing asenapine
AU2019291060B2 (en) 2018-06-20 2024-09-05 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
CN117480169A (zh) * 2021-01-08 2024-01-30 艾福姆德尤股份有限公司 用于治疗与sting活性有关的疾病的化合物和组合物
WO2022150585A1 (en) 2021-01-08 2022-07-14 Ifm Due, Inc. Heterobicyclic compounds having an urea or analogue and their compositions for treating conditions associated with sting activity
DE102022114269A1 (de) 2022-06-07 2023-12-07 Rational Aktiengesellschaft Gargerät mit einem Selbstreinigungssystem sowie ein Verfahren zum Ändern von Reinigungsparametern für das Gargerät

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5597919A (en) 1995-01-06 1997-01-28 Dull; Gary M. Pyrimidinyl or Pyridinyl alkenyl amine compounds
US5712270A (en) * 1995-11-06 1998-01-27 American Home Products Corporation 2-arylamidothiazole derivatives with CNS activity
US5616716A (en) * 1996-01-06 1997-04-01 Dull; Gary M. (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds
SE9600683D0 (sv) 1996-02-23 1996-02-23 Astra Ab Azabicyclic esters of carbamic acids useful in therapy
US5663356A (en) * 1996-04-23 1997-09-02 Ruecroft; Graham Method for preparation of aryl substituted alefinic secondary amino compounds
AR013184A1 (es) 1997-07-18 2000-12-13 Astrazeneca Ab Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis
WO1999062505A2 (en) 1998-06-01 1999-12-09 Ortho-Mcneil Pharmaceutical, Inc. Method for treating neurodegenerative disorders
US6953855B2 (en) * 1998-12-11 2005-10-11 Targacept, Inc. 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
SE9904176D0 (sv) 1999-11-18 1999-11-18 Astra Ab New use
EA005002B1 (ru) * 1999-12-10 2004-10-28 Уайт НОВЫЕ ТЕРАПЕВТИЧЕСКИЕ КОМБИНАЦИИ (S)-2-(БЕНЗИЛАМИНОМЕТИЛ)-2,3,8,9-ТЕТРАГИДРО-7H-1,4-ДИОКСИН [2,3-e]ИНДОЛ-8-ОНА И НЕЙРОЛЕПТИКОВ ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРЕДОТВРАЩЕНИЯ ПСИХОТИЧЕСКИХ РАССТРОЙСТВ
AU6610001A (en) * 2000-06-27 2002-01-08 S A L V A T Lab Sa Carbamates derived from arylalkylamines
WO2002016356A2 (en) 2000-08-18 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands)
EP1381603A2 (en) 2000-08-18 2004-01-21 PHARMACIA & UPJOHN COMPANY Quinuclidine-substituedaryl moieties for treatment of disease ( nicotinic acetylcholine receptor ligands )
US6486172B2 (en) 2000-08-18 2002-11-26 Pharmacia & Upjohn Company Quinuclidine-substituted aryl compounds for treatment of disease
EP1311505A2 (en) 2000-08-21 2003-05-21 PHARMACIA & UPJOHN COMPANY Quinuclidine-substituted heteroaryl moieties for treatment of disease ( nicotinic acetylcholine receptor ligands )
US6500840B2 (en) 2000-08-21 2002-12-31 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
AU2001284646A1 (en) 2000-08-21 2002-03-04 Pharmacia And Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
US6554086B1 (en) * 2000-10-27 2003-04-29 Invacare Corporation Obstacle traversing wheelchair
HUP0303529A3 (en) 2000-12-22 2008-03-28 Almirall Ag New quinuclidine carbamate derivatives, process for their preparation and pharmaceutical compositions containing them and their use
BR0307782A (pt) * 2002-02-19 2005-01-04 Upjohn Co Compostos azabiciclo para o tratamento de doença
JP2006510664A (ja) * 2002-12-06 2006-03-30 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー １−アザビシクロ［２．２．２］オクト置換フロ［２，３−ｃ］ピリジニルカルボキサミドの結晶性フマル酸塩及び該塩を含む組成物並びにその製造方法
TW200502222A (en) * 2003-04-02 2005-01-16 Novartis Ag Use of 10-hydroxy-10,11-dihydrocarbamazepine derivatives for the treatment of affective disorders
WO2004099202A1 (en) * 2003-05-05 2004-11-18 Pharmacia & Upjohn Company Llc Quinuclidines substituted bentodioxine carboxamides for the treatment of neurodegenerative diseases
US7309699B2 (en) * 2003-12-22 2007-12-18 Abbott Laboratories 3-Quinuclidinyl amino-substituted biaryl derivatives
CA2549638A1 (en) * 2003-12-23 2005-07-14 Pfizer Products Inc. Therapeutic combination for cognition enhancement and psychotic disorders
EP1863485A2 (en) * 2005-03-18 2007-12-12 Abbott Laboratories Alpha7 neuronal nicotinic receptor ligand and antipsychotic compositions

Also Published As

Publication number Publication date
DK2254598T3 (da) 2013-07-29
CN103143023A (zh) 2013-06-12
BRPI0907570A2 (pt) 2019-09-24
RU2481123C2 (ru) 2013-05-10
CA2715268A1 (en) 2009-08-20
RU2010137787A (ru) 2012-03-20
JP2011511845A (ja) 2011-04-14
SI2254598T1 (sl) 2013-10-30
AU2009214625A1 (en) 2009-08-20
WO2009102962A3 (en) 2009-10-08
PL2254598T3 (pl) 2013-12-31
EP2254598A2 (en) 2010-12-01
ZA201005999B (en) 2011-05-25
EP2633868A1 (en) 2013-09-04
CO6290706A2 (es) 2011-06-20
WO2009102962A2 (en) 2009-08-20
PT2254598E (pt) 2013-10-16
IL207389A0 (en) 2010-12-30
US20110059947A1 (en) 2011-03-10
EP2254598B1 (en) 2013-07-10
CY1114492T1 (el) 2016-10-05
NZ587312A (en) 2011-12-22
MX2010008875A (es) 2010-08-31
HK1147954A1 (en) 2011-08-26
HRP20130749T1 (en) 2013-10-11
CN101977628A (zh) 2011-02-16
SG188144A1 (en) 2013-03-28
ES2430622T3 (es) 2013-11-21
RS52941B (sr) 2014-02-28
KR20100113163A (ko) 2010-10-20

Similar Documents

Publication Publication Date Title
MX2010008875A (es) Agonistas nicotinicos alfa 7 y antipsicoticos.
CO6210786A2 (es) Implemento de cuidado oral que alberga un agente de cuidado oral
CL2010001428A1 (es) Compuestos derivados de amidas y tioamidas heteroaromaticas; agente que contiene al menos uno de dichos compuestos; procedimiento para combatir parasitos; y uso de dichos compuestos.
CR20110188A (es) Combinacion de una insulina y un agonista de glp-1
MX338884B (es) Composiciones y metodos que comprenden variantes de proteasa.
CL2016002589A1 (es) Uso del compuesto genz-112638 (eliglustat), inhibidor de glucosilceramida sintasa, en el tratamiento de la enfermedad de gaucher y enfermedad de fabry (divisional de solicitud 201201348).
UY33397A (es) Forma sólida de un naftaleno carboxamida
MY156511A (en) Compositions and devices
PH12013501312A1 (en) Fluid compositions comprising a structuring agent
GT200800123A (es) Compuestos mimeticos de lisina modificados
MX349787B (es) Formas de dosis oral que incluyen un agente antiplaqueta y un inhibidor de ácido.
MY155317A (en) Benzene sulfonamide thiazole and oxazole compounds
DOP2010000225A (es) Arilpirrolinas insecticidas
BR112012003705A2 (pt) composição lubrificante contendo um agente antidesgaste
HN2008000278A (es) Asociacion de un agente hipnotico de duracion de accion larga y un agente hipnotico de duracion de accion corta y su aplicacion terapeutica
BRPI0906424A2 (pt) recurso de atributo de cache extraído e instrução consequente
EA201101116A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
CL2007001457A1 (es) Preparacion oral que comprende pioglitazona o una sal de la misma y un cloruro de metal alcalino, util como hipoglicemiante.
AR067813A1 (es) Fenilendiaminas sustituidas como inhibidores de l ainteraccion entre mdm2 y p53
AR083417A1 (es) Composiciones farmaceuticas que contienen un dgat1 inhibidor
BRPI0915373A2 (pt) composições de agente de branqueamento fluorescente
BR112012003702A2 (pt) composição lubrificante contendo um agente antidesgaste
MA37650A1 (fr) Forme amorphe d'un composé pyrimidinyl-cyclopentane inhibiteur de akt, compositions et procédés de celle-ci
CR20150275A (es) Composición de difenidol de liberación prolongada
TR201109686T2 (tr) Olmesartan'ın Farmasötik Bileşimleri.